Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Articles

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.

In Interim Analysis, Mogamulizumab Demonstrates Improvements In Mycosis Fungoides, Sézary Syndrome

The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.

FDA Issues Alert on Counterfeit Botox: What Dermatology Clinicians Need to Know

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD. 

New AAD Atopic Dermatitis Guidelines and Dupilumab Label Updates

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

View

In the new millennium, we are confronted with rising overhead and decreasing reimbursements, which translates into loss of income.

clinical

Improve your collection ratio to combat lost income